Company Overview of Kythera Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate ATX-101, is an injectable drug in late-stage clinical development for the the reduction of submental fat. The company also maintains research interest in hair and fat biology, pigmentation modulation, and facial contouring. It has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United St...
30930 Russell Ranch Road
Westlake Village, CA 91362
Founded in 2004
Key Executives for Kythera Biopharmaceuticals, Inc.
Chief Financial Officer
Total Annual Compensation: $336.0K
Chief Medical Officer
Total Annual Compensation: $446.6K
Compensation as of Fiscal Year 2014.
Kythera Biopharmaceuticals, Inc. Key Developments
KYTHERA Biopharmaceuticals, Inc. Announces Board Changes
Oct 1 15
On October 1, 2015, in connection with the previously announced Amended and Restated Agreement and Plan of Merger, dated as of August 4, 2015, by and among KYTHERA Biopharmaceuticals, Inc., Allergan plc and Keto Merger Sub, Inc. In accordance with the terms of the Merger Agreement, each of Keith R. Leonard, Jr., Camille Samuels, Dennis Fenton, F. Michael Ball, Nathaniel David, Fran ois Kress, Hollings C. Renton, III and Joseph L. Turner resigned from his or her respective position as a member of KYTHERA's board of directors effective as of immediately prior to, and conditioned upon, the closing of the Merger. Upon the effectiveness of such resignations, the directors of Merger Sub as of immediately prior to the Effective Time (A. Robert D. Bailey and Maria Teresa Hilado) became the directors of the Surviving Corporation.
Kythera Biopharmaceuticals, Inc.(NasdaqGS:KYTH) dropped from NASDAQ Biotechnology Index
Sep 28 15
Kythera Biopharmaceuticals, Inc. will be removed from NASDAQ Biotech Index.
KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
Sep 22 15
KYTHERA Biopharmaceuticals, Inc. announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for KYTH-105 (setipiprant) for treatment of androgenetic alopecia (AGA), or male pattern hair loss. KYTHERA plans to conduct a human proof-of-concept study to evaluate the efficacy and safety of setipiprant in male subjects with AGA, an inherited genetic disorder that is characterized by a recession of the hairline, hair thinning and progression to partial or complete baldness in men. Setipiprant is a selective oral antagonist of the prostaglandin D2 (PGD2) receptor – a possible key variable in hair loss and is a well-characterized molecule supported by a safety database. Setipiprant has been previously evaluated by Actelion Pharmaceuticals Ltd. in nine clinical studies as a potential allergic inflammation treatment, including a Phase III trial in seasonal allergic rhinitis patients and a Phase II proof-of-concept study in asthma patients, resulting in a safety database of more than 1,000 patients with no safety issues identified. KYTHERA is pursuing the clinical development of KYTH-105 under two separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania, which provide KYTHERA with exclusive worldwide rights to KYTH-105, as well as certain patent rights covering the use of PGD2 receptor antagonists for the treatment of hair loss.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 17, 2015